+ Watch SNY
on My Watchlist
A global pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products.
Beat-up on uncertainty over BOD decisions and stock near 52-week low. Strong pipeline and undervalued relative to product portfolio and CF.
S&P 5 star stock, 46.24
My little finger
Despite trading at a discount to the European Pharma group, growth will accelerate this year (beginning in this quarter) to well above the group. Less dependent on 'cliff pharma' and more diversified into 'longer duration assets' (e.g. biologics, vaccines, animal health, branded generics and OTC, etc.). Strategic deals have uniquely positioned SNY for longer term growth (e.g. Genzyme, Regeneron and now Alnylam).
A strong position in vaccines accross the globe with a good portfolio of drugs for diabetes, cardiovascular, oncology makes this a successful diversified healthcare of proper size as number 4 in prescriptions
Devoloping Tasotere in treation non small-cell lung cancer .Peregrine hopes to serve as first step establishing its self as successful cancer -fighting agent.Is competition is catching up fast. Peregrin is using Bavituximab to treat cancer last monthreleased data showing that its antibodies produced tumor-fighting angents. Its sales of Celgene's Abrafane already has taken off.
undervalued, wide moat
Aging population (especially in Europe) will continue to increase dependency on prescription medications, also doing some great things with R&D.
Good year for health care...even in Europe
High Volume Breakout on 02/08/13
EPS $6.90 TP $60
Attach "Europe based" to nearly any company in this fall of 2012, and expect a measurable price discount. Add to that SNY's history of drug development and management coupled with the change growing population of drug consumers (read, more baby boomers aging), and you have a winner.
Above average drug portfolio. Growth of existing and new products should more than make up for patent expirations.
no innovation, big patent cliff with Plavix/Lovenox/Lantus...nothing to replace them. Stock has done little over the past few years.
India based biotech in under-represented market
Dividend makes is "safer" in the short run but with pipeline and genzyme long term also looks good
This stock is a Cramer favorite with a decent 3.8% yeild. Cramer believes this company has a low valuation, and is an accidental high yeilder. Ken Fisher of Fisher Asset Management recently increased holdings to over 14,750,000 shares.
Strong pipeline and nice dividend make SNY a compelling buy at this price.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions